Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Tumor-Agnostic 1

Conditions

Carcinoma, Basal Cell 2Melanoma 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Acitretin × Dermatologic × Clear all
NCT02050321 2018-12-26

A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

University of Arizona

Phase 2 Terminated
2 enrolled 7 charts
Dermatologic

Melanoma

NCT00003611 2016-07-13

Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation

Alliance for Clinical Trials in Oncology

Phase NA Completed
129 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT00644384 2011-05-16

Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer

Mayo Clinic

Phase NA Completed
130 enrolled
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡